Pre-Transplant Azacitidine and Allogeneic Hematopoietic Cell Transplant (HCT) Outcomes of One Hundred Fifty-Nine Patients up to Age Seventy-Five with Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
Year: 2014
Type: article
Study design: Observational Study
Abstract: HCT is the only known curative treatment for MDS. Treatment with the DNA methyltransferase inhibitor azacitidine (aza) has been utilized prior to HCT for tumor debulking and to slow leukemic progression. To discern the impact of aza treatment, we retrospectively analyzed the post transplant outcomes of 159 patients (pts) according to pre-HCT aza exposure. Patients included those with a diagnosis of MDS or CMML at any time point in their disease course and subsequently received a HCT. Eligible patients proceeded to HCT if they had adverse disease features such as elevated IPSS risk, treatment related MDS, progression or refractory disease.
Authors: Teresa Field, Janelle Perkins, Ryan Hillgruber, Taiga Nishihori, Marcie R. Tomblyn, Asmita Mishra, Joseph Pidala, Frederick Locke, Lia Elena Perez, Brian Betts, Ernesto Ayala, Melissa Alsina, Jose-Leonel Ochoa, Eric Padron, Jeffery Lancet, Hugo Fernandez, Alan F. List, Rami Komrokji, Mohamed Kharfan-Dabaja, Claudio Anasetti
Institution: Moffitt Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2312893276